U.S. Gene Therapy Market Size, Share & Trends Analysis Report By Indication (Multiple Myeloma, Spinal Muscular Atrophy, Inherited Retinal Disease), By Route Of Administration, By Vector Type (Lentivirus, AAV, Adenovirus), And Segment Forecasts, 2024 - 2030

Table of Contents

Chapter 1. Methodology and Scope
                   1.1. Market Segmentation and Scope
                       1.1.1. Indication Segment
                       1.1.2. Route of Administration Segment
                       1.1.3. Vector Type Segment
                   1.2. Estimates and Forecast Timeline
                   1.3. Research Methodology
                   1.4. Information Procurement
                       1.4.1. Purchased Database
                       1.4.2. GVR’s Internal Database
                       1.4.3. Primary Research
                   1.5. Information or Data Analysis:
                       1.5.1. Data Analysis Models
                   1.6. Market Formulation & Validation
                   1.7. Model Details
                       1.7.1. Commodity Flow Analysis
                   1.8. List of Secondary Sources
                   1.9. List of Abbreviations
                   1.10. Objective
Chapter 2. Executive Summary
                   2.1. Market Outlook
                   2.2. Segment Snapshot
                   2.3. Competitive Landscape Snapshot
Chapter 3. Market Variables, Trends, & Scope
                   3.1. Market Lineage Outlook
                       3.1.1. Parent Market Outlook
                       3.1.2. Related/Ancillary Market Outlook
                   3.2. Market Dynamics
                       3.2.1. Market Driver Analysis
                           3.2.1.1. Robust gene therapy pipeline
                           3.2.1.2. Introduction of technological advancements
                           3.2.1.3. Growing prevalence of target diseases
                           3.2.1.4. Increasing investments from companies and partnerships
                       3.2.2. Market Restraint Analysis
                           3.2.2.1. High prices of gene therapy
                           3.2.2.2. Limited manufacturing capacity
                   3.3. Industry Analysis Tools
                       3.3.1. Porter’s Five Forces Analysis
                       3.3.2. PESTEL Analysis
                       3.3.3. COVID-19 Impact Analysis
Chapter 4. Indication Business Analysis
                   4.1. Indication Segment Dashboard
                   4.2. U.S. Gene Therapy Market Indication Movement Analysis
                   4.3. U.S. Gene Therapy Market Size & Trend Analysis, by Indication, 2018 to 2030 (USD Million)
                   4.4. Large B-Cell Lymphoma
                       4.4.1. Large B-cell lymphoma market estimates and forecasts, 2018 - 2030 (USD Million)
                   4.5. Multiple Myeloma
                       4.5.1. Multiple myeloma market estimates and forecasts, 2018 - 2030 (USD Million)
                   4.6. Spinal Muscular Atrophy (SMA)
                       4.6.1. Spinal muscular atrophy (SMA) market estimates and forecasts, 2018 - 2030 (USD Million)
                   4.7. Acute Lymphoblastic Leukemia (ALL)
                       4.7.1. Acute lymphoblastic leukemia (ALL) market estimates and forecasts, 2018 - 2030 (USD Million)
                   4.8. Melanoma (Lesions)
                       4.8.1. Melanoma (lesions) market estimates and forecasts, 2018 - 2030 (USD Million)
                   4.9. Inherited Retinal Disease
                       4.9.1. Inherited retinal disease market estimates and forecasts, 2018 - 2030 (USD Million)
                   4.10. Beta-Thalassemia Major/SCD
                       4.10.1. Beta-thalassemia major/SCD market estimates and forecasts, 2018 - 2030 (USD Million)
                   4.11. Others
                       4.11.1. Others market estimates and forecasts, 2018 - 2030 (USD Million)
Chapter 5. Route of Administration Business Analysis
                   5.1. Route of Administration Segment Dashboard
                   5.2. U.S. Gene Therapy Market Route of Administration Movement Analysis
                   5.3. U.S. Gene Therapy Market Size & Trend Analysis, by Route of Administration, 2018 to 2030 (USD Million)
                   5.4. Intravenous
                       5.4.1. Intravenous market estimates and forecasts, 2018 - 2030 (USD Million)
                   5.5. Others
                       5.5.1. Others market estimates and forecasts, 2018 - 2030 (USD Million)
Chapter 6. Vector Type Business Analysis
                   6.1. Vector Type Segment Dashboard
                   6.2. U.S. Gene Therapy Market Vector Type Movement Analysis
                   6.3. U.S. Gene Therapy Market Size & Trend Analysis, by Vector Type, 2018 to 2030 (USD Million)
                   6.4. Lentivirus
                       6.4.1. Lentivirus market estimates and forecasts, 2018 - 2030 (USD Million)
                   6.5. RetroVirus & gamma RetroVirus
                       6.5.1. RetroVirus & gamma retrovirus market estimates and forecasts, 2018 - 2030 (USD Million)
                   6.6. AAV
                       6.6.1. AAV market estimates and forecasts, 2018 - 2030 (USD Million)
                   6.7. Modified Herpes Simplex Virus
                       6.7.1. Modified herpes simplex virus market estimates and forecasts, 2018 - 2030 (USD Million)
                   6.8. Adenovirus
                       6.8.1. Adenovirus market estimates and forecasts, 2018 - 2030 (USD Million)
                   6.9. Others
                       6.9.1. Others market estimates and forecasts, 2018 - 2030 (USD Million)
Chapter 7. Competitive Landscape
                   7.1. Company Categorization
                   7.2. Strategy Mapping
                   7.3. Company Market Position Analysis, 2023
                   7.4. Company Profiles/Listing
                       7.4.1. Amgen Inc.
                           7.4.1.1. Overview
                           7.4.1.2. Financial Performance
                           7.4.1.3. Product Benchmarking
                           7.4.1.4. Strategic Initiatives
                       7.4.2. Novartis AG
                           7.4.2.1. Overview
                           7.4.2.2. Financial Performance
                           7.4.2.3. Product Benchmarking
                           7.4.2.4. Strategic Initiatives
                       7.4.3. F. Hoffmann-La Roche
                           7.4.3.1. Overview
                           7.4.3.2. Financial Performance
                           7.4.3.3. Product Benchmarking
                           7.4.3.4. Strategic Initiatives
                       7.4.4. Gilead Sciences, Inc.
                           7.4.4.1. Overview
                           7.4.4.2. Financial Performance
                           7.4.4.3. Product Benchmarking
                           7.4.4.4. Strategic Initiatives
                       7.4.5. bluebird bio, Inc.
                           7.4.5.1. Overview
                           7.4.5.2. Financial Performance
                           7.4.5.3. Product Benchmarking
                           7.4.5.4. Strategic Initiatives
                       7.4.6. Bristol-Myers Squibb Company
                           7.4.6.1. Overview
                           7.4.6.2. Financial Performance
                           7.4.6.3. Product Benchmarking
                           7.4.6.4. Strategic Initiatives
                       7.4.7. Legend Biotech.
                           7.4.7.1. Overview
                           7.4.7.2. Financial Performance
                           7.4.7.3. Product Benchmarking
                           7.4.7.4. Strategic Initiatives
                       7.4.8. BioMarin.
                           7.4.8.1. Overview
                           7.4.8.2. Financial Performance
                           7.4.8.3. Product Benchmarking
                           7.4.8.4. Strategic Initiatives
                       7.4.9. uniQure N.V.
                           7.4.9.1. Overview
                           7.4.9.2. Financial Performance
                           7.4.9.3. Product Benchmarking
                           7.4.9.4. Strategic Initiatives
                       7.4.10. Merck & Co.
                           7.4.10.1. Overview
                           7.4.10.2. Financial Performance
                           7.4.10.3. Product Benchmarking
                           7.4.10.4. Strategic Initiatives
                       7.4.11. Sarepta Therapeutics, Inc.
                           7.4.11.1. Overview
                           7.4.11.2. Financial Performance
                           7.4.11.3. Product Benchmarking
                           7.4.11.4. Strategic Initiatives
                       7.4.12. Krystal Biotech, Inc.
                           7.4.12.1. Overview
                           7.4.12.2. Financial Performance
                           7.4.12.3. Product Benchmarking
                           7.4.12.4. Strategic Initiatives
                       7.4.13. CRISPR Therapeutics.
                           7.4.13.1. Overview
                           7.4.13.2. Financial Performance
                           7.4.13.3. Product Benchmarking
                           7.4.13.4. Strategic Initiatives

List of Tables

Table 1 List of secondary sources
Table 2 List of abbreviation
Table 3 U.S. gene therapy market, by indication, 2018 - 2030 (USD Million)
Table 4 U.S. gene therapy market, by route of administration, 2018 - 2030 (USD Million)
Table 5 U.S. gene therapy market, by vector type, 2018 - 2030 (USD Million)
Table 6 Key companies undergoing expansions
Table 7 Key companies undergoing acquisitions
Table 8 Key companies undergoing collaborations
Table 9 Key companies launching new products/services
Table 10 Key companies undertaking other strategies

List of Figures

Fig. 1 Market research process
Fig. 2 Data triangulation techniques
Fig. 3 Primary research pattern
Fig. 4 Market research approaches
Fig. 5 Market formulation & validation
Fig. 6 U.S. gene therapy market: market outlook
Fig. 7 U.S. gene therapy competitive insights
Fig. 8 Parent market outlook
Fig. 9 U.S. gene therapy market driver impact
Fig. 10 U.S. gene therapy market restraint impact
Fig. 11 U.S. gene therapy market: Indication movement analysis
Fig. 12 U.S. gene therapy market: Indication outlook and key takeaways
Fig. 13 Large B-cell lymphoma market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 14 Multiple myeloma market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 15 Spinal muscular atrophy (SMA) market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 16 Acute lymphoblastic leukemia (ALL) market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 17 Melanoma (lesions) market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 18 Inherited retinal disease market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 19 Beta-thalassemia major/SCD market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 20 Others market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 21 U.S. gene therapy market: Route of administration movement analysis
Fig. 22 U.S. gene therapy market: Route of administration outlook and key takeaways
Fig. 23 Intravenous market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 24 Others market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 25 U.S. gene therapy market: Vector type movement analysis
Fig. 26 U.S. gene therapy market: Vector type outlook and key takeaways
Fig. 27 Lentivirus market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 28 RetroVirus & gamma retrovirus market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 29 AAV market estimates and forecasts,2018 - 2030 (USD Million)
Fig. 30 Modified herpes simplex virus market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 31 Adenovirus market estimates and forecasts,2018 - 2030 (USD Million)
Fig. 32 Others market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 33 Market share of key market players - U.S. gene therapy market